The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.
CNS Neuroscience & Therapeutics March 1, 2025 Zerui You, Xiaofeng Lan, Chengyu Wang et al. 1 citation
Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mechanisms underlying this await comprehensive explication. We used metabolomics to find biomarkers for ketamine efficacy and uncover its mechanisms of action. The study included 40 MDD patients treated with ketamine in the discovery cohort and 24...
DOI: 10.1111/cns.70324 (opens in new tab)
Full text (opens in new tab)
Major depressive disorder
Mental health research
Metabolic biomarkers
Metabolomic
+3